Pacific Edge Limited (PEB) Price & Analysis

Based in Dunedin, New Zealand, Pacific Edge Limited, established in 2001, operates as a cancer diagnostics firm. The company's core mission involves the research, development, and commercialization of advanced diagnostic and prognostic tools aimed at the early identification and ongoing management of various cancers. Its diagnostic solutions are accessible in New Zealand, the United States, Australia, and Singapore, with operations structured across Commercial and Research segments. A key offering is the Cxbladder suite, a collection of genomic urine tests specifically designed for detecting and managing bladder cancer. Within this suite, Cxbladder Resolve aids in identifying patients likely to present with more aggressive or advanced bladder cancer. Cxbladder Triage helps pinpoint individuals with haematuria who exhibit a low probability of bladder cancer, while Cxbladder Detect offers a non-invasive method for identifying bladder and other urinary tract cancers. Furthermore, Cxbladder Monitor facilitates continuous surveillance for disease recurrence in bladder cancer patients. Beyond its focus on bladder cancer, Pacific Edge is actively developing additional diagnostic innovations. These include Cxcolorectal, a prognostic gene signature for assessing outcomes in patients diagnosed with stage II or stage III colorectal cancers, alongside pipeline products targeting gastric, endometrial cancers, and melanoma.